Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (RAINFOL-05)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants.
The purpose of this study is to evaluate how well Rina-S works against lung cancer.
The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo.
The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a Phase 2, open-label, multicenter, multi-cohort trial to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of Rina-S as monotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), with or without select genomic aberrations.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Genmab Trial Information
- Phone Number: +4570202728
- Email: clinicaltrials@genmab.com
Study Locations
-
-
-
Adelaide, Australia
- Recruiting
- St Andrews Medical Centre
-
Blacktown, Australia
- Recruiting
- Blacktown Hospital
-
Camperdown, Australia
- Recruiting
- Chris O'Brien Lifehouse
-
Fitzroy, Australia
- Recruiting
- St Vincent's Hospital - Melbourne
-
Hobart, Australia
- Recruiting
- Icon Cancer Centre Hobart
-
Hyde Park, Australia
- Recruiting
- Icon Cancer Care - Townsville
-
Hyde Park, Australia
- Recruiting
- Icon Cancer Centre Townsville ICON Cancer Care - Townsville
-
Kogarah, Australia
- Recruiting
- St George Hospital
-
Murdoch, Australia
- Recruiting
- St John of God Murdoch Hospital
-
Nedlands, Australia
- Recruiting
- Sir Charles Gairdner Hospital
-
Saint Leonards, Australia
- Recruiting
- GenesisCare North Shore
-
-
-
-
-
Edegem, Belgium
- Recruiting
- Universitair Ziekenhuis Antwerpen
-
Hasselt, Belgium
- Recruiting
- Jessa Ziekenhuis - Campus Virga Jesse
-
La Louvière, Belgium
- Recruiting
- Chu Helora Hospital La Louvière Site Jolimont
-
Leuven, Belgium
- Recruiting
- UZ Leuven - Gasthuisberg Campus
-
Roeselare, Belgium
- Recruiting
- AZ Delta (Campus Wilgenstraat)
-
-
-
-
-
Beijing, China
- Recruiting
- Beijing Cancer Hospital
-
Beijing, China
- Recruiting
- Beijing Chest Tumor Hospital
-
Changchun, China
- Recruiting
- Jilin Provincial Cancer Hospital
-
Nanjing, China
- Recruiting
- Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital)
-
Tianjin, China
- Recruiting
- Tianjin Medical University Cancer Institute and Hospital
-
Zhangjiakou, China
- Recruiting
- The First Affiliated Hospital of Hebei North University
-
Zhengzhou, China
- Recruiting
- Henan Cancer Hospital
-
-
Pudong
-
Shanghai, Pudong, China
- Recruiting
- Shanghai East Hospital
-
-
-
-
-
Marseille, France
- Recruiting
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
Paris, France
- Recruiting
- Groupe Hospitalier Paris Saint-Joseph
-
Paris, France
- Recruiting
- Cochin Hospital
-
Paris, France
- Recruiting
- Institut Curie - Centre de Recherche
-
Pierre-Bénite, France
- Recruiting
- Lyon Sud Hospital Center
-
-
-
-
-
Berlin, Germany
- Recruiting
- Evangelische Lungenklinik Berlin
-
Essen, Germany
- Recruiting
- Universitaetsklinikum Essen
-
Halle, Germany
- Recruiting
- Krankenhaus Martha-Maria Halle-Dölau
-
Heidelberg, Germany
- Recruiting
- Thoraxklinik-Heidelberg
-
-
-
-
-
Kecskemét, Hungary
- Recruiting
- Bács-Kiskun Megyei Kórház - Kecskemét
-
Tatabánya, Hungary
- Recruiting
- Szent Borbála Hospital
-
-
-
-
-
Candiolo, Italy
- Recruiting
- Istituto di Candiolo - IRCCS
-
Meldola, Italy
- Recruiting
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
-
Orbassano, Italy
- Recruiting
- Azienda Ospedaliero Universitaria San Luigi Gonzaga
-
Ravenna, Italy
- Recruiting
- Ospedale Santa Maria delle Croci
-
Roma, Italy
- Recruiting
- Policlinico Agostino Gemelli
-
-
-
-
-
Chūō, Japan
- Recruiting
- National Cancer Center - Tsukiji Campus
-
Tokyo, Japan
- Recruiting
- Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
-
-
Kanagawa
-
Sagamihara, Kanagawa, Japan
- Recruiting
- Kitasato University Hospital
-
Yokohama, Kanagawa, Japan
- Recruiting
- Kanagawa Cardiovascular and Respiratory Center
-
-
Kyoto
-
Kyoto, Kyoto, Japan
- Recruiting
- Kyoto Prefectural University of Medicine
-
-
Minami Ward
-
Nagoya, Minami Ward, Japan
- Recruiting
- Japan Community Health Care Organization Chukyo Hospital
-
-
Moroyama
-
Saitama, Moroyama, Japan
- Recruiting
- Saitama Medical University International Medical Center
-
-
Osaka
-
Sakai, Osaka, Japan
- Recruiting
- NHO Kinki Chuo Chest Medical Center
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- The Netherlands Cancer Institute (NKI)
-
Leiden, Netherlands
- Recruiting
- Leids Universitair Medisch Centrum
-
Nijmegen, Netherlands
- Recruiting
- Radboudumc
-
-
-
-
-
Gdansk, Poland
- Recruiting
- Gdański Uniwersytet Medyczny
-
Krakow, Poland
- Recruiting
- KOMED Roman Karaszewski I Wspolnicy Spolka Jawna
-
Lodz, Poland
- Recruiting
- Instytut MSF
-
Poznan, Poland
- Recruiting
- MedPolonia
-
-
-
-
-
Cheongju-si, South Korea
- Recruiting
- Chungbuk National University Hospital
-
Daegu, South Korea
- Recruiting
- Keimyung University Dongsan Hospital
-
Incheon, South Korea
- Recruiting
- Gachon University Gil Medical Center
-
Seoul, South Korea
- Recruiting
- Korea University Anam Hospital
-
Suwon, South Korea
- Recruiting
- The Catholic University Of Korea St. Vincent's Hospital
-
-
-
-
-
A Coruña, Spain
- Recruiting
- Hospital Teresa Herrera
-
Barcelona, Spain
- Recruiting
- Parc de Salut Mar - Hospital del Mar
-
Barcelona, Spain
- Recruiting
- USP Instituto Universitario Dexeus
-
Barcelona, Spain
- Recruiting
- Hospital Germans Trias i Pujol
-
Las Palmas de Gran Canaria, Spain
- Recruiting
- Hospital Universitario Insular de Gran Canaria
-
Logroño, Spain
- Recruiting
- START Rioja
-
Madrid, Spain
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Recruiting
- Hospital General Universitario Gregorio Marañón
-
Madrid, Spain
- Recruiting
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid, Spain
- Recruiting
- MD Anderson Cancer Center Madrid
-
Madrid, Spain
- Recruiting
- Clinica Universidad de Navarra - Madrid
-
Málaga, Spain
- Recruiting
- Hospital Quirón Málaga
-
Pamplona, Spain
- Recruiting
- Clinica Universidad de Navarra - Pamplona
-
Valencia, Spain
- Recruiting
- Fundación IVO. Instituto Valenciano de Oncología
-
Valencia, Spain
- Recruiting
- Hospital Clinico Universitario de Valencia
-
-
-
-
-
Changhua, Taiwan
- Recruiting
- Changhua Christian Hospital
-
Kaohsiung City, Taiwan
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taiwan
- Recruiting
- Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
-
Tainan, Taiwan
- Recruiting
- Chi Mei Medical Center - Liouying
-
Tainan, Taiwan
- Recruiting
- National Cheng Kung University
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital (NTUH)
-
-
-
-
California
-
Fountain Valley, California, United States, 92708
- Recruiting
- Compassionate Cancer Care Center
-
Irvine, California, United States, 92618
- Recruiting
- City of Hope Orange County Lennar Foundation Cancer Center
-
San Diego, California, United States, 92108
- Recruiting
- Kaiser Permanente San Diego Mission Road
-
Santa Rosa, California, United States, 95403
- Recruiting
- Providence Medical Foundation (St. Joseph Heritage Healthcare)
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20007
- Recruiting
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami Hospital
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Winship Cancer Institute
-
-
Montana
-
Billings, Montana, United States, 59102
- Recruiting
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Recruiting
- Nebraska Hematology-Oncology
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Recruiting
- Astera Cancer Care
-
-
New York
-
Albany, New York, United States, 12206
- Recruiting
- ONE Onc: New York Oncology Hematology
-
The Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Park
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- UNC Health - University of North Carolina
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Recruiting
- Williamette Valley Cancer Institute and Research Center
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Portland Medical Center
-
West Haven-Sylvan, Oregon, United States, 97225
- Recruiting
- Providence Oncology & Hematology Care Clinic - Westside
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology Nashville - SCRI Oncology Partners
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Baylor Charles A. Sammons Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Virginia Cancer Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.
- Participant must have radiological disease progression while on or after receiving the most recent regimen.
- Participants either may have actionable genetic alterations (AGAs) or no AGAs.
- Participant has measurable disease according to RECIST v1.1.
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1.
Key Exclusion Criteria (all study cohorts):
- Participant has NSCLC with histology other than adenocarcinoma
- Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.
- Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease). Participants with history of spinal cord compression (from disease). Participants with previous CNS-directed therapy (eg, radiotherapy and/or surgery) for brain metastases may participate provided lesion(s) are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging.
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Rina-S
Multiple cohorts (Cohorts A, B, C, D, and E) will receive Rina-S as monotherapy. |
Intravenous (IV) infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of Response (DOR) per RECIST v1.1 as Assessed by Investigator
Time Frame: Approximately 4 years
|
Approximately 4 years
|
|
Disease Control Rate (DCR) per RECIST v1.1 as Assessed by Investigator
Time Frame: Approximately 4 years
|
Approximately 4 years
|
|
Progression-free Survival (PFS)
Time Frame: Approximately 4 years
|
Approximately 4 years
|
|
Overall Survival (OS)
Time Frame: Approximately 4 years
|
Approximately 4 years
|
|
Maximum (Peak) Observed Serum Drug Concentration (Cmax) of Rina-S Related Analytes
Time Frame: Approximately 12 months
|
Approximately 12 months
|
|
Time to Reach Maximum (Peak) Serum Drug Concentration (Tmax) of Rina-S Related Analytes
Time Frame: Approximately 12 months
|
Approximately 12 months
|
|
Number of Participants with Antidrug Antibodies (ADAs)
Time Frame: Approximately 12 months
|
Approximately 12 months
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Approximately 4 years
|
Approximately 4 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Official, Genmab
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GCT1184-05
- 2025-522107-18-00 (Ctis)
- jRCT2041250176 (Registry Identifier: Japan Registry for Clinical Trials (jRCT))
- CTR20260819 (Registry Identifier: Chinadrugtrials.org.cn)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.